Zevra Therapeutics/$ZVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Zevra Therapeutics
Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.
Ticker
$ZVRA
Sector
Primary listing
Employees
61
Headquarters
Website
ZVRA Metrics
BasicAdvanced
$542M
6.84
$1.35
0.94
-
Price and volume
Market cap
$542M
Beta
0.94
52-week high
$13.16
52-week low
$6.19
Average daily volume
1.2M
Financial strength
Current ratio
5.678
Quick ratio
5.455
Long term debt to equity
40.598
Total debt to equity
40.869
Interest coverage (TTM)
-0.53%
Profitability
EBITDA (TTM)
-0.179
Gross margin (TTM)
84.52%
Net profit margin (TTM)
78.17%
Operating margin (TTM)
-3.98%
Effective tax rate (TTM)
3.98%
Revenue per employee (TTM)
$1,750,000
Management effectiveness
Return on assets (TTM)
-1.14%
Return on equity (TTM)
85.66%
Valuation
Price to earnings (TTM)
6.837
Price to revenue (TTM)
4.795
Price to book
3.39
Price to tangible book (TTM)
3.66
Price to free cash flow (TTM)
-209.835
Free cash flow yield (TTM)
-0.48%
Free cash flow per share (TTM)
-0.044
Growth
Revenue change (TTM)
350.91%
Earnings per share change (TTM)
-159.18%
3-year revenue growth (CAGR)
118.83%
3-year earnings per share growth (CAGR)
20.26%
10-year earnings per share growth (CAGR)
-36.09%
What the Analysts think about ZVRA
Analyst ratings (Buy, Hold, Sell) for Zevra Therapeutics stock.
ZVRA Financial Performance
Revenues and expenses
ZVRA Earnings Performance
Company profitability
ZVRA News
AllArticlesVideos
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Newsfile Corp·4 weeks ago
Zevra Therapeutics Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Zevra Therapeutics stock?
Zevra Therapeutics (ZVRA) has a market cap of $542M as of March 21, 2026.
What is the P/E ratio for Zevra Therapeutics stock?
The price to earnings (P/E) ratio for Zevra Therapeutics (ZVRA) stock is 6.84 as of March 21, 2026.
Does Zevra Therapeutics stock pay dividends?
No, Zevra Therapeutics (ZVRA) stock does not pay dividends to its shareholders as of March 21, 2026.
When is the next Zevra Therapeutics dividend payment date?
Zevra Therapeutics (ZVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Zevra Therapeutics?
Zevra Therapeutics (ZVRA) has a beta rating of 0.94. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.